<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Some immunizations for travel</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Some immunizations for travel</h1>
<div class="graphic"><div class="figure"><div class="ttl">Some immunizations for travel</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Vaccines</td> <td class="subtitle1">Adult dose</td> <td class="subtitle1">Pediatric age/dose</td> <td class="subtitle1">Standard primary schedule</td> <td class="subtitle1">Duration of protection</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Hepatitis A</td> </tr> <tr> <td class="indent1">Havrix</td> <td>1 mL IM (1440 EU)</td> <td>1 to 18 years: 0.5 mL IM (720 EU).</td> <td>0 and 6 to 12 months.</td> <td class="divider_bottom" rowspan="2">Probably lifelong after completion of primary series.*</td> </tr> <tr class="divider_bottom"> <td class="indent1">Vaqta</td> <td>1 mL IM (50 units)</td> <td>1 to 18 years: 0.5 mL IM (25 units).</td> <td>0 and 6 to 18 months.</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Hepatitis B</td> </tr> <tr> <td class="indent1">Engerix-B</td> <td>1 mL IM (20 mcg)</td> <td>Birth to 19 years: 0.5 mL IM (10 mcg).</td> <td>0, 1, and <span class="nowrap_whitespace">6 months.<sup>¶</sup><sup>Δ</sup></span></td> <td class="divider_bottom" rowspan="3">Probably lifelong after completion of primary series.</td> </tr> <tr> <td class="indent1">Recombivax-HB</td> <td>1 mL IM (10 mcg)</td> <td>Birth to 19 years: 0.5 mL IM (5 mcg).</td> <td>0, 1, and <span class="nowrap_whitespace">6 months.<sup>Δ</sup><sup>◊</sup></span></td> </tr> <tr class="divider_bottom"> <td class="indent1">Heplisav-B</td> <td>0.5 mL IM (20 mcg)</td> <td>Not approved for &lt;18 years.</td> <td>0, 28 days.</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Hepatitis A/B</td> </tr> <tr class="divider_bottom"> <td class="indent1">Twinrix</td> <td>1 mL IM (720 EU/20 mcg)</td> <td>Not approved for &lt;18 years.</td> <td>0, 1, and 6 months (alternative: 0, 7, and 21 to 30 days).</td> <td>Booster recommended at 12 months with accelerated schedule; otherwise, probably lifelong after completion of primary series.</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Japanese encephalitis</td> </tr> <tr class="divider_bottom"> <td class="indent1">Ixiaro (JE-VC)</td> <td> <p>Age 18 to 65: 0.5 mL IM/dose; two doses (first dose on day 0; second dose any time between day 7 and day 28)</p> Age &gt;65: 0.5 mL IM/dose; two doses given on days 0 and 28</td> <td> <p>Age 2 months to &lt;3 years: 0.25 mL IM/dose; two doses given on days 0 and 28.</p> Age ≥3 years: Same as for adults &gt;65.</td> <td>Schedule varies with age (see preceding columns).</td> <td>A single booster &gt;1 year after completion of primary series if ongoing <span class="nowrap_whitespace">risk.<sup>§</sup></span></td> </tr> <tr> <td class="subtitle2_left" colspan="5">Meningococcus</td> </tr> <tr> <td class="indent1">Menveo</td> <td>0.5 mL IM (10 mcg serogroup A, 5 mcg serogroup C, Y, W135)</td> <td>≥2 years: 0.5 mL IM (10 mcg serogroup A, 5 mcg serogroup C, Y, W135).</td> <td>≥2 to 55 years: Single <span class="nowrap_whitespace">dose.<sup>¥</sup></span></td> <td>Repeat every <span class="nowrap_whitespace">5 years<sup>‡</sup></span> if ongoing risk.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Menactra</td> <td>0.5 mL IM (4 mcg of each antigen)</td> <td>≥9 months: 0.5 mL IM 4 mcg of each antigen.</td> <td> <p>9 to 23 months: 0, 3 months.</p> ≥2 to 55 years: Single dose.</td> <td>Repeat every <span class="nowrap_whitespace">5 years<sup>‡</sup></span> if ongoing risk.</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Rabies</td> </tr> <tr> <td class="indent1">Imovax (HDCV)</td> <td>1 mL IM (≥2.5 international units of rabies antigen)</td> <td>All ages: 1 mL IM (≥2.5 international units of rabies antigen).</td> <td>0 and 7 days. Empiric third dose between day 21 and <span class="nowrap_whitespace">3 years.<sup>†,</sup>**</span></td> <td class="divider_bottom" rowspan="2">Third dose unnecessary if titer check at 1 to 3 years shows protective <span class="nowrap_whitespace">levels.**</span></td> </tr> <tr class="divider_bottom"> <td class="indent1">RabAvert (PCECV)</td> <td>1 mL IM (≥2.5 international units of rabies antigen)</td> <td>All ages: 1 mL IM (≥2.5 international units of rabies antigen).</td> <td>0 and 7 days. Empiric third dose between day 21 and <span class="nowrap_whitespace">3 years.<sup>†,</sup>**</span></td> </tr> <tr> <td class="subtitle2_left" colspan="5">Typhoid</td> </tr> <tr> <td class="indent1">Vivotif</td> <td>1 cap PO (contains 2 to <span class="nowrap_whitespace">6 × 10<sup>†</sup></span> viable colony-forming units of <em>S.</em> Typhi Ty21a)</td> <td>≥6 years: 1 cap PO (contains 2 to <span class="nowrap_whitespace">6 × 10<sup>†</sup></span> viable colony-forming units of <em>S.</em> Typhi Ty21a).</td> <td>1 cap every other day × 4 doses.</td> <td>Repeat every 5 years if ongoing risk.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Typhim Vi</td> <td>0.5 mL IM (25 mcg)</td> <td>≥2 years: 0.5 mL IM (25 mcg).</td> <td>Single dose.</td> <td>Repeat every 2 years (3 years in Canada) if ongoing risk.</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Yellow fever</td> </tr> <tr class="divider_bottom"> <td class="indent1">YF-Vax</td> <td>0.5 mL SC <span class="nowrap_whitespace">(4.74 log<sup>¶¶</sup></span> plaque forming units of 17D204 attenuated YF virus)</td> <td>≥9 months: 0.5 mL SC <span class="nowrap_whitespace">(4.74 log<sup>¶¶</sup></span> plaque forming units of 17D204 attenuated YF virus).</td> <td>Single dose.</td> <td>Booster dose every 10 years if ongoing risk.</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Cholera</td> </tr> <tr class="divider_bottom"> <td class="indent1">Vaxchora</td> <td>Aged 18 to 64: 100 mL PO (lyophilized <em>Vibrio cholerae</em> CVD 103-HgR)</td> <td> <p>Age 2 to &lt;6: 50 mL by mouth (lyophilized <em>V. cholerae</em> CVD 103-HgR).</p> Age ≥6 years: Same as for adults.</td> <td>Single dose.</td> <td>No specific recommendation; consider booster every 6 months if at continued risk.</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Tick-borne encephalitis vaccine</td> </tr> <tr> <td class="indent1">Ticovac (known as FSME/IMMUN in some European countries)</td> <td>Age 16 years and older: 0.5 mL IM/dose; three doses (first dose on day 0, second dose <span class="nowrap_whitespace">14 days<sup>ΔΔ</sup></span> to 3 months after the first dose, third dose 5 to 12 months after the second dose)</td> <td>Age 1 to 15 years: 0.25 mL IM/dose; three doses (first dose on day 0, second dose 1 to 3 months after the first dose, third dose 5 to 12 months after the second vaccination).</td> <td>Schedule varies with age (see preceding columns).</td> <td>A booster dose (fourth dose) may be given at least 3 years after completion of the primary series if ongoing exposure or re-exposure to tickborne encephalitis virus is expected.</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>IM: intramuscular; SC: subcutaneous; PO: by mouth; JE-VC: Vero cell culture-derived Japanese encephalitis; HDCV: human diploid cell vaccine; PCECV: purified chick embryo cell vaccine; PrEP: pre-exposure prophylaxis; ACIP: Advisory Committee on Immunization Practices; MMWR: Morbidity and Mortality Weekly Report.</p>
<p>* Protection likely lasts at least 12 months after a single dose.</p>
<p>¶ An alternate schedule is three doses given at 0, 1, and 2 months, followed by a fourth dose at 12 months.</p>
<p>Δ An accelerated schedule of 0, 7, and 14 days followed by a booster dose at 6 months has been used but is not US Food and Drug Administration-approved.</p>
<p>◊ An alternate schedule for adolescents 11 to 15 years old is 0 and 4 to 6 months.</p>
<p>§ Adults previously vaccinated with JE Vax should receive a primary series of <span class="nowrap_whitespace">Ixiaro.<sup>[1]</sup></span></p>
<p>¥ For children 2 to 5 years old at continued high risk, a second dose may be administered two months after the first.</p>
<p>‡ Repeat after 3 years for children vaccinated at &lt;7 years of age. Considerable published data indicates that protection significantly wanes after 3 years; travelers to the meningitis belt should consider a booster after 3 years due to the high risk of infection compared to risk at <span class="nowrap_whitespace">home.<sup>[2]</sup></span></p>
<p>† Regimen for PrEP. If a previously vaccinated traveler is exposed to a potentially rabid animal, postexposure prophylaxis with 2 additional vaccine doses separated by 3 days should be initiated as soon as possible.</p>
<p>** For immunocompetent individuals with short-term risk for rabies (such as travelers), the World Health Organization and the United States Centers for Disease Control and Prevention endorse a 2-dose PrEP <span class="nowrap_whitespace">regimen.<sup>[3,4]</sup></span> For those at ongoing risk, such as long-stay or frequent travelers, an empiric booster (third) dose may be given between day 21 and 3 years; alternatively, such individuals may have antibody levels checked at 1 to 3 years postvaccination, with booster (third) dose if antibody titer is &lt;0.5 international units/mL. Thereafter, no further titers are needed, and no further vaccine doses are needed unless postexposure prophylaxis is warranted following an exposure.</p>
<p>¶¶ Minimal acceptable antibody level is complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test.</p>
ΔΔ Short-stay travelers are protected a week after a second dose given at day 14 but should receive either the third dose or a titer check at 1 to 3 years is further exposure is expected.</div><div class="graphic_reference">References:
<ol>
<li>Centers for Disease Control and Prevention. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: Advisory committee on immunization practices, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:661.</li>
<li>Cohn AC, MacNeil JR, Harrison LH. Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine. Pediatrics 2017; pii: e20162193.</li>
<li>World Health Organization. Rabies vaccine: WHO position paper - April 2018. Wkly Epidemiol Rec 2018; 93:201. Available at: <a href="http://apps.who.int/iris/bitstream/handle/10665/272371/WER9316.pdf?ua=1" target="_blank">http://apps.who.int/iris/bitstream/handle/10665/272371/WER9316.pdf?ua=1</a> (Accessed on October 11, 2021).</li>
<li>Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP). Available at: <a href="https://www.cdc.gov/vaccines/acip/recommendations.html" target="_blank">https://www.cdc.gov/vaccines/acip/recommendations.html</a> (Accessed on October 11, 2021).</li>
</ol>
<p class="extra_spacing_top">Adapted with special permission from: Treatment Guidelines from The Medical Letter, June 2012; Vol. 10 (118):45. <a href="http://www.medicalletter.org" target="_blank">www.medicalletter.org</a>.</p></div><div id="graphicVersion">Graphic 82688 Version 18.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
